收藏切换
Application of vericiguat combined with dapagliflozin in patients with heart failure with reduced ejection fraction
收藏切换
Aifen LU, Guijia ZHU, Zhikuan FENG, Junyou LIU, Ke ZHANG
World Clinical Drug | 2024, 45(12) : 1269 - 1275
Less
收藏切换
World Clinical Drug | 2024, 45(12): 1269-1275
• Article •
Application of vericiguat combined with dapagliflozin in patients with heart failure with reduced ejection fraction
Full
Aifen LU, Guijia ZHU, Zhikuan FENG, Junyou LIU, Ke ZHANG
Affiliations
  • Department of Cardiology, Puyang Oilfield General Hospital, Puyang 457001, Henan Province, China
Published: 2024-12-10 doi: 10.13683/j.wph.2024.12.009
Outline
收藏切换
Objective

To observe the effect of vericiguat combined with dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).

Methods

A total of 98 patients with HFrEF in our hospital from January 2023 to January 2024 were selected and divided into combination group and control group according to random number table method, with 49 cases in each group. On the basis of conventional HF treatment, the control group was given dapagliflozin, the combination group was given dapagliflozin combined with vericiguat. Both groups were treated for 6 months. The clinical effect, adverse reactions, HF rehospitalization rate and major adverse cardiovascular event (MACE) were compared between the two groups. The cardiac function indexes, N-terminal brain natriuretic peptide precursor (NT-proBNP), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), Minnesota living with heart failure questionnaire (MLHFQ) score, 6-minute walking test (6MWT) distance were compared between the two groups before and after treatment.

Results

After treatment, the total effective rate of combination group was higher than that of control group (93.62% vs 70.83%, P<0.05). The LVEF level and 6MWT distance were increased in both groups, and the combination group was higher than the control group (P<0.05). The levels of LVEDD, LVESD, NT-proBNP, NLR, CRP and MLHFQ score were all decreased, and the combination group was lower than the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P<0.05). The incidence of HF rehospitalization (6.38% vs 20.83%, P<0.05) and MACE (12.77% vs 31.25%, P<0.05) in the combination group were lower than those in the control group, respectively.

Conclusion

Vericiguat combined with dapagliflozin can significantly reduce ventricular remodeling and inflammatory response in HFrEF patients, enhance efficacy, improve quality of life and prognosis, and have good safety.

vericiguat  /  dapagliflozin  /  heart failure with reduced ejection fraction  /  ventricular remodeling
鲁爱粉, 朱贵家, 冯治宽, 刘军友, 张可. 维立西呱联合达格列净在射血分数减低型心力衰竭患者中的应用观察. 世界临床药物, 2024 , 45 (12) : 1269 -1275 . DOI: 10.13683/j.wph.2024.12.009
Aifen LU, Guijia ZHU, Zhikuan FENG, Junyou LIU, Ke ZHANG. Application of vericiguat combined with dapagliflozin in patients with heart failure with reduced ejection fraction[J]. World Clinical Drug, 2024 , 45 (12) : 1269 -1275 . DOI: 10.13683/j.wph.2024.12.009
Year 2024 volume 45 Issue 12
24
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.12.009
  • Receive Date:2024-03-28
  • Online Date:2026-11-17
  • Published:2024-12-10
Article Data
Affiliations
History
  • Received:2024-03-28
  • Revised:2024-07-12
Affiliations
    Department of Cardiology, Puyang Oilfield General Hospital, Puyang 457001, Henan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.12.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT